Amneal touts 26 generic new product launches in 2022

2022 was a very productive year for Amneal. The company successfully launched 26 new generic products.

In the fourth quarter of 2022, Amneal launched eight new generic products, including clindamycin phosphate gel 1%, ipratropium bromide nasal sprays and prednisolone sodium phosphate oral solution.

“2022 was another successful year of innovation for Amneal. Across the portfolio we continue to innovate, further expand our portfolio of essential medicines, and drive incremental impact and benefit for healthcare professions and their patients. Looking to 2023, we expect more than 30 new product launches,” said Chirag Patel and Chintu Patel, Amneal co-CEOs.

[Read more: Amneal debuts 2 generics]

In addition, Amneal also announced it received ANDA approval from the Food and Drug Administration for its first large-volume bag, esmolol hydrochloride in sodium chloride injection.

Harsher Singh, senior vice president for Amneal Biosciences, stated, “We are seeing continued momentum in expanding our injectables business. We are excited about this first ready to use bag approval utilizing one of our new manufacturing sites and look forward to more over the coming months.”